Published on February 11, 2025, in Hepatology, this study sheds light on the persistent global burden of hepatitis B virus (HBV)-related liver cancer. While significant progress has been made in HBV prevention and treatment, disparities in liver cancer prevalence remain a major concern. The findings reveal that in 2021, there were 7.3 million cases of acute HBV, 283.6 million cases of HBV-related cirrhosis, and 288,110 cases of HBV-related liver cancer. Shockingly, HBV-related liver cancer accounted for 39% of all primary liver cancer cases worldwide, with the highest incidence recorded in the Western Pacific region.
Despite declines in overall HBV-related disease burden, the incidence of HBV-related liver cancer increased in 65 countries from 2000 to 2021, particularly in Europe and the Americas. This trend highlights an urgent need for strengthened HBV screening, vaccination, and treatment strategies to curb liver cancer risks. The study underscores the importance of continuous efforts to improve HBV management and prevent further escalation of liver cancer cases.
A special thanks to the experts who contributed to this crucial research. For more insights.
Refer to the full: https://lnkd.in/eEr7ayym
